Research & Regulatory News

Orforglipron in the UK: Access, Cost and the NHS Question

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Foundayo holds a UK marketing authorisation but is not funded by the NHS. Access is currently through private prescription after clinical assessment, with reported monthly costs ranging from about £99 to £179 depending on strength and provider. NHS availability depends on NICE guidance, first due on 18 November 2026 and now expected on 27 January 2027.

Key facts

Authorised
10 August 2026 (MHRA)
Route to access
Private prescription after clinical assessment
Reported monthly cost
Approximately £99-£179
NHS status
Not funded
NICE guidance due
27 January 2027 (moved from 18 November 2026)
Likely NHS prescribing
Not before 2027 if recommended

Authorisation is not availability

These are two separate decisions made by two separate bodies. The MHRA assesses whether a medicine is safe, effective and of adequate quality, and grants a marketing authorisation on that basis. Whether the NHS pays for it is decided afterwards by NICE, which assesses cost-effectiveness. A medicine can be fully licensed in the UK and still be unavailable on the NHS for a year or more, which is the position Foundayo is in.

What access looks like at the moment

Supply is through registered pharmacies on private prescription, following a clinical assessment against the licensed criteria: a BMI of 30 or above, or 27 to 30 with at least one weight-related comorbidity. Reported monthly costs have ranged from around £99 for lower strengths to roughly £149-£179 at higher strengths, varying by provider. Prices reported at launch tend to move.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What NICE is deciding

NICE guidance was due on 18 November 2026. After a second committee meeting on 10 November 2026, NICE now expects to publish it on 27 January 2027. The appraisal weighs clinical effectiveness against cost per quality-adjusted life year, and considers the size of the eligible population. For obesity medicines that population is very large, and it is the reason previous incretin appraisals have come with tight eligibility criteria and managed-access arrangements rather than open prescribing.

Why the tablet format matters commercially

Orforglipron is manufactured by conventional organic synthesis rather than peptide synthesis or recombinant expression. That is substantially cheaper and easier to scale, and supply constraints have been a real limitation on injectable incretins. Cost-effectiveness arguments at NICE turn partly on price, and a compound without a peptide manufacturing bottleneck has more room on that axis.

A necessary distinction

Foundayo is a prescription-only medicine, assessed and supplied through regulated clinical channels. It is not related to research material, and nothing supplied for laboratory research is an alternative to it, a generic of it, or a route to obtaining it. We do not supply it and this article is not a purchasing guide.

Frequently asked questions

Can I get Foundayo on the NHS?

Not at the time of writing. It is licensed, and NHS funding depends on NICE, whose guidance is now expected on 27 January 2027 (it was first due on 18 November 2026).

What does it cost privately?

Reported figures at launch ranged from roughly £99 to £179 a month depending on strength and provider. Launch pricing commonly changes.

Why is it licensed but not available on the NHS?

Licensing and funding are separate decisions. The MHRA assesses safety and efficacy; NICE assesses cost-effectiveness afterwards.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.